Association between acetaminophen use and vitiligo in US women and men

Abstract

AbstractBackground/ObjectivesExposure to chemical phenols, which can act as tyrosine analogues and result in anti‐melanocyte autoimmunity, has been associated with vitiligo. Acetaminophen (N‐acetyl‐p‐aminophenol) is an over‐the‐counter analgesic of phenolic origin. The risk of vitiligo with systemic exposure to acetaminophen has not yet been evaluated.MethodsWe examined the risk of vitiligo with regular use acetaminophen in women, the Nurses' Health Study (NHS) and in men, the Health Professionals Follow‐up Study (HPFS). Regular acetaminophen use was asked biennially from 1990 in NHS and from 1986 in HPFS, and the year of clinician‐diagnosed vitiligo was asked retrospectively in 2012 in the cohorts.ResultsIn NHS, a total of 161 vitiligo cases were identified during a follow‐up of 571,724 person‐years; in HPFS, a total of 183 vitiligo cases were identified during a follow‐up of 680,313 person‐years. Regular use of acetaminophen was associated with an increased vitiligo risk in NHS but not HPFS. The multivariable relative risk (RR) was 1.52 (95% confidence interval [CI] 1.03–2.25) in NHS and 1.09 (95% CI 0.76–1.55) in HPFS. The higher risk of vitiligo was similar by duration of acetaminophen use in women; the multivariable RRs were 1.47 (95% CI 0.98–2.21) for acetaminophen use under 5 years, and 1.78 (95% CI 1.11–2.84) for acetaminophen use over 5 years.ConclusionsAcetaminophen may be associated with a higher risk of vitiligo in women.